We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
- Authors
Santoro, Cristina; Sperduti, Isabella; Latagliata, Roberto; Baldacci, Erminia; Anaclerico, Barbara; Avvisati, Giuseppe; Breccia, Massimo; Buccisano, Francesco; Cedrone, Michele; Cimino, Giuseppe; De Gregoris, Cinzia; De Muro, Marianna; Di Veroli, Ambra; Leonetti Crescenzi, Sabrina; Montanaro, Marco; Montefusco, Enrico; Porrini, Raffaele; Rago, Angela; Spadea, Antonio; Spirito, Francesca
- Abstract
Aim of this study is to explore the role of different treatments on the development of secondary malignancies ( SMs) in a large cohort of essential thrombocythemia ( ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea ( HU); group 2, alkylating agents ( ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide ( ANA) and/or α-interferon ( IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender ( P = 0.035) and age ( P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [ CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [ CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.
- Subjects
THROMBOCYTOPENIA treatment; HYDROXYUREA; INTERFERON alpha; ANAGRELIDE; ALKYLATING agents
- Publication
Cancer Medicine, 2017, Vol 6, Issue 6, p1233
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.1081